@entity1068 and XXXX After Intraperitoneal Administration to @entity36739 -Knockout @entity19 -Reflection in Blood and Brain Levels.

@entity30166 @entity167 @entity7097 @entity36739 @entity19 @entity7084 @entity3451 @entity1068 @entity3094
This paper reports, for the first time, on the analysis of @entity1068 ( @entity167 ) and @entity3094 ( @entity3451 ) concentrations in the blood and brains of @entity36739 -knockout ( @entity36739 -KO) and C57B6/6J ( @entity7097 ) @entity19 . Animals were administrated @entity167 (1.0, 2.0 or 4.0  g/kg) or @entity7084 ( @entity30166 , 82  mg/kg) plus @entity3451 (50, 100 or 200  mg/kg) intraperitoneally. During the blood tests, samples from the orbital sinus of the eye were collected. During the brain tests, dialysates were collected every 5  min (equal to a 15    l sample) from the striatum using in vivo brain microdialysis. Samples were collected at 5, 10, 15, 20, 25, 30 and 60  min intervals post- @entity167 and - @entity3451 injection, and then analyzed by head-space GC. In the @entity167 groups, high @entity3451 levels were found in the blood and brains of @entity36739 -KO @entity19 , while only small traces of @entity3451 were seen in the blood and brains of @entity7097 @entity19 . No significant differences in @entity167 levels were observed between the @entity7097 and the @entity36739 -KO @entity19 for either the @entity167 dose. @entity167 concentrations in the brain were comparable to the @entity167 concentrations in the blood, but the @entity3451 concentrations in the brain were four to five times lower compared to the @entity3451 concentrations in the blood. In the @entity3451 groups, high @entity3451 levels were found in both @entity7097 and @entity36739 -KO @entity19 . Levels reached a sharp peak at 5  min and then quickly declined for 60  min. Brain @entity3451 concentrations were almost equal to the concentrations found in the blood, where the @entity3451 concentrations were approximately two times higher in the @entity36739 -KO @entity19 than in the @entity7097 @entity19 , both in the blood and the brain. Our results suggest that systemic @entity167 and @entity3451 administration can cause a greater increase in @entity3451 accumulation in the blood and brains of @entity36739 -KO @entity19 , where @entity167 concentrations in the @entity36739 -KO @entity19 were comparable to the @entity167 concentrations in the @entity7097 @entity19 . Furthermore, detection of @entity167 and @entity3451 in the blood and brain was found to be dose-dependent in both genotypes.
